Target specific management of IBD is the need of the hour. It is very important to understand the pathophysiology of IBD to optimize clinical outcomes. Therapeutic goals today are: Induce clinical remission, Maintain clinical remission, Improve quality of life along with avoidance of drug related and disease related complications, decrease hospitalization & overall costs. We will learn about: What is the Pathophysiology of IBD? What are the Risk factors, Diagnosis and Clinical presentation? What are the emerging therapeutic strategies for managing a case of IBD along with clinical case discussion of Crohn’s/Ulcerative colitis in Indian clinical practice.

Targeting the pathophysiology of IBD to optimize clinical outcomes

Biologics have revolutionized the management of IBD. Past expectations were symptom control and improve quality of life. Therapeutic goals today are: Induce clinical remission, Maintain clinical remission, Improve quality of life along with avoidance of drug related and disease related complications. Decrease hospitalisation & overall costs. We will learn When we should use biologics? When would we consider early biologic therapy in IBD and selecting first line biologic therapy for IBD.

Early modification of inflammatory burden in IBD patients by biologics

Senior Consultant, Department of Gastroenterology and Hepato-biliary Sciences | Fortis Memorial Research Institute, Gurugram

Dr. Rinkesh Bansal

2

502

9.3K

4.5

Sessions Taken

236

4.6

277

4.4